Clinical Trials Logo
  1. Home
  2. Oligometastatic Disease
  3. NCT05128201

Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma — NPC-CR01  

Oligometastatic Disease Clinical Trial

Official title:
Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma: A Multicenter, Open-Label, Phase II Trial (NPC-CR01)

Clinical Trial Summary

The purpose of this study is to explore the efficacy and tolerance of local consolidative radiotherapy combined with Camrelizumab and chemotherapy in patients with oligometastatic nasopharyngeal carcinoma

Clinical Trial Description

This trial was a single-arm, multicenter phase Ⅱ clinical study. Eligible oligometastatic NPC patients were scheduled to evaluate the efficacy and tolerance of local consolidative radiotherapy combined with camrelizumab and chemotherapy in patients with oligometastatic NPC. Progression-free survival (PFS) determined will be the primary outcome measures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05128201
Study type Interventional
Source Jiangxi Provincial Cancer Hospital
Contact
Status Recruiting
Phase Phase 2
Start date December 1, 2021
Completion date May 31, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Not yet recruiting NCT06373497 - Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography Early Phase 1
Recruiting NCT05377047 - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer N/A
Recruiting NCT05223803 - TERPS Trial for de Novo Oligometastic Prostate Cancer Phase 2
Recruiting NCT04617457 - Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas Phase 2
Recruiting NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer Phase 2
Recruiting NCT05679427 - Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions N/A
Recruiting NCT05277844 - Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC Phase 2
Active, not recruiting NCT05951127 - Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC N/A
Active, not recruiting NCT05101824 - Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease N/A
Not yet recruiting NCT06430411 - Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
Recruiting NCT04748042 - Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) Phase 2
Recruiting NCT06122480 - Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma N/A
Not yet recruiting NCT05784428 - Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression N/A
Completed NCT04593381 - Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer N/A
Terminated NCT01345539 - Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation Phase 2
Recruiting NCT05846646 - Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC Phase 2
Recruiting NCT04973007 - Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases Phase 4
Recruiting NCT06439888 - Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT05917431 - Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC Phase 2